Close Menu

NEW YORK (GenomeWeb) – Personal Genome Diagnostics has entered into a strategic collaboration with China's KingMed Diagnostics to use PGDx's Elio tissue complete assay to detect tumor mutational burden and other gene variants.

Separately, PGDx said it has also partnered with Merck as part of a phase II precision oncology study.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.